Investment Rating - The investment rating for the company is "Buy" [8] Core Views - The company reported a significant increase in net profit for Q3 2024, with a year-on-year growth of 126.85% [4] - Revenue for the first nine months of 2024 reached 196.76 million, representing an 18.20% increase year-on-year [4] - The gross profit margin slightly improved to 38.39% for the first nine months of 2024, up by 2.99 percentage points year-on-year [4] Financial Performance Summary - For the first nine months of 2024, the company achieved a net profit of 37.40 million, a decrease of 6.98% year-on-year, while the non-recurring net profit increased by 28.87% to 34.34 million [4] - In Q3 2024, the company generated revenue of 59.35 million, a year-on-year increase of 37.17% [4] - The company's net profit margin for Q3 2024 was 13.31%, an increase of 7.15 percentage points year-on-year [4] - The company's total assets amounted to 529.46 million, with net assets of 471.14 million [1] Business Overview - The company specializes in the research, development, production, and sales of high-end pharmaceutical intermediates and active pharmaceutical ingredients, with a focus on complex structures and high technical barriers [2]
峆一药业：Q3归母净利润提升较大，收入稳步增长